FDA Pushes for Onshoring and Improved Data Fidelity in Generic Drug User Fee (GDUFA IV) Negotiations

FDA; onshoring; data fidelity; generic drugs; user fee; GDUFA IV; manufacturing; bioequivalence; public health; performance metrics

Trump Tariffs Poised to Hit Drug Tool and Packaging Manufacturers: Industry Faces Rising Costs and Supply Chain Challenges

Trump tariffs , Drug packaging industry , Pharmaceutical supply chain , API manufacturing costs , Biopharma trade war , U.S. manufacturing onshoring , Generic drugs market impact , Pharmaceutical tariffs , Supply chain disruption , Pharmaceutical industry lobbying